Novartis AG operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Novartis AG with three other
companies in this sector in the United States:
sales of $53.65 billion
of which 62%
was Operating Segment-Global Innovative Phar),
of which 42%
was Pharmaceuticals & Biological Products), and
Roche Holding Aktiengesellschaft
of which 77%
Novartis AG reported sales of $53.17 billion
December of 2018.
increase of 6.0%
versus 2017, when the company's sales were $50.14 billion.
The sales level in 2018 was fairly close to the level five years ago: in 2013, Novartis AG had sales
of $58.83 billion.
Sales of Alcon saw an increase
that was more than double the company's growth rate: sales were up
18.7% in 2018, from
$6.02 billion to $7.15 billion.
Not all segments of Novartis AG experienced an increase in sales in 2018:
sales of Sandoz fell 2.0% to $9.86 billion.